



REATA.

June 29, 2023

BY ELECTRONIC DELIVERY

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highestprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Reata Pharmaceuticals, Inc. is providing notice of the introduction of a new prescription drug with a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program:

- Product: Skyclarys 50 mg which is used for the treatment of Friedreich ataxia in adults and children 16 years of age and older
- NDC: 73179-0250-90

This notice is provided within three calendar days following the release of the drug in the commercial market, as required by 18 V.S.A. § 4637(b). 18 V.S.A. § 4637 does not define “release of the drug in the commercial market,” therefore, we have based our three-day notice on the date that the product became available for purchase by patients, June 28th, 2023.

Sincerely,

Micheline Taptich

Financial Operations Controller

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
972.865.2219
www.reatapharma.com